BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age

BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age

This case-control study of US children examines vaccine effectiveness rates of a messenger RNA vaccine during the 2023-2024 respiratory virus season.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA network open 2024-12, Vol.7 (12), p.e2449944
Hauptverfasser: Tartof, Sara Y, Frankland, Timothy B, Puzniak, Laura, Slezak, Jeff M, Ackerson, Bradley K, Hong, Vennis, Stern, Julie, Zamparo, Joann M, Chowdhry, Hina, Spence, Brigitte, Davis, Gregg S, Jodar, Luis, McLaughlin, John M
Format: Artikel
Sprache:eng
Schlagworte:
Infectious Diseases
Online Only
Research Letter
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This case-control study of US children examines vaccine effectiveness rates of a messenger RNA vaccine during the 2023-2024 respiratory virus season.
ISSN:2574-3805
2574-3805
DOI:10.1001/jamanetworkopen.2024.49944